Last update 17 Apr 2025

AMT-116(Multitude Therapeutics)

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms-
Target
CD44 x Tubulin
Action
inhibitors
Mechanism
CD44 inhibitors(CD44 antigen inhibitors), Tubulin inhibitors
Therapeutic Areas
Neoplasms
Active Indication
Advanced Malignant Solid NeoplasmSolid tumor
Inactive Indication-
Originator Organization
Multitude Therapeutics, Inc.
Active Organization
Multitude, Inc.Multitude, Inc.Multitude Therapeutics, Inc.Multitude Therapeutics, Inc. (China)Multitude Therapeutics, Inc. (China)
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC11H22N4O4
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N
CAS Registry159858-33-0
View All Structures (2)
Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

3
Clinical Trials associated with AMT-116(Multitude Therapeutics)
NCT06782334
/ RecruitingPhase 1/2
Phase 1/2 Study of AMT-116 in Patients with Advanced Solid Tumors
CTR20240804
/ RecruitingPhase 1/2
评价一种自主研发的ADC药物 AMT-116 在晚期实体瘤患者中的I/II期研究
[Translation] A Phase I/II study evaluating AMT-116, an independently developed ADC drug, in patients with advanced solid tumors
NCT05725291
/ RecruitingPhase 1
First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors
100 Clinical Results associated with AMT-116(Multitude Therapeutics)
Login to view more data
100 Translational Medicine associated with AMT-116(Multitude Therapeutics)
Login to view more data
100 Patents (Medical) associated with AMT-116(Multitude Therapeutics)
Login to view more data
100 Deals associated with AMT-116(Multitude Therapeutics)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
China
Multitude Therapeutics, Inc.
07 May 2024
Solid tumorIND Approval
China
Multitude Therapeutics, Inc. (China)Multitude Therapeutics, Inc. (China)
18 Jan 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT05725291 (ASCO2024)
Phase 1
Advanced Malignant Solid Neoplasm
CD44v9
8
AMT-116 3 mg/kg
buwezbduym(jthwdxjtti) = No DLT events were observed dddomfoziu (qhufofzvjt )
View more
Positive
24 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free